Important Safety Information

EnLyte® is indicated for the distinct nutritional requirements of individuals who have suboptimal folate levels in the cerebrospinal fluid, plasma and/or red blood cells, and require a maintenance level. Folate is effective in the treatment of hyperhomocysteinemia and/or megaloblastic anemias (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, childhood or other related folate-malabsorption complications of an inborn or environmental origin.

EnLyte® is not a drug, but may be used as monotherapy ("rescue" therapy) or adjunctive therapy as determined by your licensed medical practitioner. The adjunctive use of EnLyte® enables medical practitioners to combine therapeutic modalities (dietary management and drug therapy). In patients with suboptimal folate levels - and as determined by your licensed medical practitioner, EnLyte® may be administered as rescue or adjunctive folate-therapy to provide a protective effect in reducing the risk of secondary/endpoints and/or disease-states of a hyperhomocysteinemia and/or vascular nature such as may be found with depression; or EnLyte® may be administered as rescue or adjunctive folate-therapy to provide a protective effect in reducing the risk of secondary/endpoints and/or disease-states of a hyperhomocysteinemia and/or methylation metabolic imbalance as may be found with depressed patients.

EnLyte® is contraindicated in individuals with a known hypersensitivity to any of the ingredients. EnLyte® is contraindicated for individuals with conditions for which any of the EnLyte® ingredients are contraindicated. EnLyte® is also contraindicated for individuals who would be negatively affected by increased monoamine neurotransmitter synthesis.

Allergic sensitization has been reported following both oral and parenteral administration of folate. Paresthesia, somnolence, nausea, and headaches have been reported with vitamin B₆. Mild transient diarrhea, polycythemia vera, itching, transitory exanthema and the feeling of swelling of the entire body have been associated with vitamin B₁₂.

It is important to always contact your health practitioner if you experience any side effects while on EnLyte®.

Daily ingestion of more than 3 grams per day of omega-3 fatty acids (ALA, EPA, and DHA) from fish oils may have potential antithrombotic activities, or effects, and may increase bleeding times. Administration of omega-3 fatty acids, including DHA, should be avoided in individuals with inherited or acquired bleeding diathesis, including those taking anticoagulants. Exercise caution to ensure that the prescribed dosage of DHA does not exceed 1 gram (1000 mg) per day.

Please see full prescribing information.